A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.
RAISE: Niraparib added to anti-PD-L1 antibody maintenance in SLFN11-positive, extensive-disease SCLC
An international, multicentre, single-arm phase II trial in patients with extensive-disease small cell lung cancer and high SLFN11-expression who have not progressed during first-line standard chemo-immunotherapy and are planned for maintenance therapy with immune-checkpoint inhibition .
Trial Scheme
